Study of SmartMatch Testing to Guide Treatment in People 15 Years and Older With Advanced Central Nervous System Tumors

What this Trial Is About

Primary central nervous system CNS tumors, which include recurrent gliomas and other rare brain tumors, are challenging to treat and often have poor outcomes. This research evaluates a new AI-driven technology called SmartMatch, developed to analyze how tumor tissue samples respond to various FDA-approved drugs. The goal is to see if SmartMatch can provide drug response results within 21 days after tumor tissue is collected to help doctors explore better treatment options for patients with advanced CNS tumors. During the study, participants who are scheduled for tumor biopsy or surgery at NIH will have small tumor samples collected as part of their planned procedure. These fresh samples will be analyzed using the SmartMatch platform to generate drug response data. Blood samples will also be collected for additional molecular profiling. The study does not require any extra procedures beyond what is planned for clinical care. Participants will be followed remotely every six months for up to three years to monitor their health and any disease progression. The research team will review how quickly and effectively the SmartMatch platform completes the drug screen analysis and will gather molecular information about the tumors over time. The study aims to improve understanding of CNS tumors and support the development of more precise treatments in the future.

Observational Study of Responses to Treatments in Advanced Central Nervous System (CNS) Tumors